| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Urology [P. P., C. P. N. D.] and Cancer Biology [T. M., K. I., H. K., B. Y. E., R. R.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and ImClone Systems, New York, New York [D. J. H.]
 |
ABSTRACT |
|---|
 Top ABSTRACT IntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
|
Introduction |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
EGFR signaling and angiogenesis have been independently evaluated as targets for therapy, but the link between has only recently been identified (17, 18, 19, 20, 21, 22, 23, 24)
. Both EGF and TGF-
, which are ligands for EGFR, induce angiogenesis. Therefore, we hypothesized that down-regulating EGFR signaling pathways may inhibit tumor growth by inhibiting tumor-mediated angiogenesis, independent of any direct cytostatic effect on tumor growth. We recently reported that therapy with either protein tyrosine kinase inhibitors (20)
or anti-EGFR MAb C2254
inhibited the growth of established human TCC growing orthotopically in athymic nude mice. We now report that therapy with MAb C225 reduces TCC neovascularization by down-regulating the tumor cell expression of the angiogenic factors VEGF, IL-8, and bFGF, resulting in abrogation of tumor growth and metastasis.
|
Materials and Methods |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
Animals.
Male athymic BALB/c nude mice were obtained from the Animal Production Area of the National Cancer Institute, Frederick Cancer Research Facility (Frederick, MD). The mice were maintained in a laminar air-flow cabinet under pathogen-free conditions and used at 8–12 weeks of age. All facilities were approved by the American Association for Accreditation of Laboratory Animal Care in accordance with United States Department of Agriculture, Department of Health and Human Services, and NIH standards.
Antibodies.
Chimeric anti-EGFR MAb C225 was generously provided by ImClone Systems, Inc. (New York, NY). Human IgG (Sigma Biosciences, St. Louis, MO) was used as a control.
In Vitro Therapy of Tumor Cells.
The in vitro dose-dependent antiproliferative effect of MAb C225 was evaluated by incubating 253J B-V cells for 24 h in serum-free medium, then exchanging the medium for 0%, 1%, or 10% FBS-supplemented EMEM containing increasing concentrations of MAb C225 (0.08–10 µg/ml). Growth inhibition was determined by [3H]thymidine incorporation after a 72-h incubation period. To evaluate expression of VEGF, IL-8, and bFGF after therapy with MAb C225, 5 x 103 cells were plated in a 96-well plate in 200 µl of EMEM supplemented with 10% FBS, then treated the next day with 1 µg/ml or 10 µg/ml of MAb C225. Ten percent FBS-supplemented EMEM without MAb C225 and EGFR-irrelevant human IgG (10 µg/ml) served as controls. After treatment, cells were counted, and both the supernatant and the cells were collected and stored at -20°C for protein quantification. To evaluate the influence of EGFR activation on the expression of the angiogenic factors, exogenous EGF (50 ng/ml) was added to stimulate EGFR signaling pathways. Cell-associated bFGF and supernatant VEGF and IL-8 protein levels were measured using the commercially available Quantine ELISA kit (R&D Systems, Inc., Minneapolis, MN). Steady-state mRNA expression was determined by Northern blot analysis.
Northern Blot Analysis.
Polyadenylated mRNA was extracted from 108 cells growing in culture with the FastTrack mRNA isolation kit (Invitrogen Co., San Diego, CA). The mRNA was electrophoresed on 1% denaturing formaldehyde/agarose gel and electrotransferred to Genescreen nylon membrane (DuPont Co., Boston, MA), using a UV Stratalinker 1800 cross-linked with 120,000 µJ/cm2. Filters were washed at 55°C with 30 mM sodium citrate and 0.1% SDS (w/v). The membranes were then hybridized and probed for VEGF, bFGF, IL-8, and ß-actin as a control. The cDNA probes used were: (a) a Jird actin 1.2-kb DNA fragment (26)
; (b) a 1.4-kb cDNA fragment of bovine bFGF (27)
; (c) a 204-bp BamHI EcoRI fragment of human VEGF cDNA (28)
; and (d) a 0.5-kb EcoRI cDNA fragment corresponding to human IL-8 (a gift from Dr. K. Matsushima, Kanazawa, Japan; Ref. 29
). The probes were radiolabeled by a random primer technique and [-32P]dCTP (Amersham Corp., Arlington Heights, IL). Autoradiography of the membrane was performed after washing. Densitometry scanning permitted quantitation of the bands.
Orthotopic Implantation of Tumor Cells.
For the in vivo portion of the study, cultured 253J B-V cells (70% confluent) were prepared for injection, as previously described (25)
. Mice were anesthetized with methoxyflurane, a lower midline incision was made, and the bladder was exposed. Viable tumor cells (1 x 106/0.05 ml of HBSS) were injected into the wall of the bladder. The formation of a bulla was the sign of a satisfactory injection. The bladder was returned into the abdominal cavity, and the abdominal wall was closed in a single layer with metal clips.
Therapy of Established Human TCC Tumors Growing in the Bladders of Athymic Nude Mice.
Treatment commenced 28 days after tumor implantation. The presence and volume of tumors were confirmed using ultrasound or palpation. At the time of therapy, tumor weights were between 200 and 400 mg. Mice were randomly separated into two groups. The first group (eight mice) was treated with 1 mg of anti-EGFR chimeric antibody MAb C225 i.p. twice a week for 5 weeks. Eight control mice received an equivalent volume of PBS on the same schedule. Treated mice were closely monitored for any signs of progressive disease and sacrificed if they became moribund. Control mice were sacrificed at or about 5 weeks after tumor implantation because they became moribund. To evaluate the temporal effects of MAb C225 on angiogenic factor expression and microvessel density, mice were sacrificed 1, 3, and 5 weeks after initiation of therapy.
Necropsy.
Necropsy was performed, and local tumorigenicity and distant metastases (lymph node and lung nodules) were determined. The bladders were harvested, weighed, and either mechanically dissociated for in vitro culture, flash-frozen in liquid nitrogen for mRNA extraction, or cut in two and either embedded in Optimal Cutting Temperature gel (Sokera Inc., Torrence, CA) for frozen sections or fixed in 10% buffer and formalin for paraffin sections. The lymph nodes were fixed in formalin. Lungs were mechanically dissociated for reestablishment in culture to evaluate the presence of micrometastases or fixed in Bouin’s fluid for histological analysis.
Immunohistochemical Determination of bFGF, VEGF, and IL-8.
The expression of angiogenic factors was detected in cryostat (IL-8) or paraffin sections (bFGF, VEGF) of tumors treated with either MAb C225 or PBS (30)
. bFGF protein expression was detected using primary rabbit anti-bFGF (Sigma Chemical Co., St. Louis, MO), which reacts with residues 147–153 and shows no cross-reaction with acidic fibroblast growth factor. VEGF and IL-8 proteins were detected using primary rabbit antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:1200 dilution. The -immunoperoxidase technique for immunohistochemical staining was used with a second peroxidase-conjugated goat antirabbit antibody (IgG, F[ab]2 fragment; Jackson ImmunoResearch Laboratory, Inc., West Grove, PA; Ref. 30
).
Quantification of Microvessel Density.
Cryostat sections of bladder tumor were fixed with acetone and chloroform solutions for 15 min and then washed twice with PBS. Endogenous peroxidase was blocked with 3% hydrogen peroxide in methanol, and the sections were washed with PBS and incubated overnight in a protein-blocking solution. The excess blocking solution was removed, and the samples were incubated with the rat antimouse CD31 antibody that stains endothelial cells (PharMingen, San Diego, CA). Swine peroxidase conjugated antirabbit antibody was applied for 30 min after the primary antibody was removed. The samples were rinsed with PBS and developed with 3-amino-9-ethylcarbazole at room temperature for 20 min. The sections were counterstained with aqueous hematoxylin. A positive reaction was indicated by a brownish precipitate (30)
.
Two investigators counted the microvessels independently in a blinded fashion. The tissues were examined at low power (x40), and the three x200 fields of highest microvessel density were identified for vessel counts. The three selected fields (high-power field, x20 objective and x10 ocular, 0.739 mm2/field) were recorded using a computer-linked cooled CCD Optotronics Tec 470 camera (Optotronics Engineering, Goletha, CA) to ensure that both investigators would count the same areas within the specimens. Microvessels were quantitated according to the method described by Weidner et al. (31) . Clusters of stained endothelial cells distinct from adjacent microvessels, tumor cells, or other stromal cells were counted as one microvessel. The results were expressed as the highest number of microvessels identified within a single x200 field.
In Situ mRNA Hybridization.
Paraffin sections of fixed tissue (3–5 µm) were mounted on ProbOn slides (Fisher Scientific, Pittsburgh, PA). The slides were dewaxed and prepared, and ISH was performed using the Microprobe system (Fisher Scientific) as described previously (32
, 33)
. Slides were rinsed three times in Tris buffer for 30 s; hybridization of the probes was then performed at 45°C for 45 min. The slides were washed with 2 x SSC three times for 2 min each time at 45°C. The samples were then incubated with avidin labeled with phosphatase for 30 min at 45°C, rinsed in 50 mM Tris buffer (pH 7.6), and then briefly (1 min) rinsed in alkaline phosphatase. The samples were then incubated with chromogen substrate for 20 min at 45°C. If necessary, additional incubation was performed with fresh chromogen to enhance a weak reaction. The samples were then covered with Universal Mount fixative (Research Genetics, Huntsville, AL), heat-dried, and examined. A positive reaction in this assay stained red. To control for endogenous alkaline phosphatase, additional samples were treated in the absence of biotinylated probe. No immunoreactivity was observed in the controls.
Densitometry Quantification of Immunohistochemical and In Situ mRNA Hybridization.
The intensity of immunohistochemical staining and in situ mRNA hybridization was evaluated in five fields representing areas of highest staining intensity. Each field was evaluated using the ImageQuant analyzer and Optimas software program (Bioscan, Edmonds, WA). Immunohistochemical staining intensity of each specimen was compared with the staining intensity of the normal urothelium in the same sample and expressed as a ratio (tumor cells:normal urothelium). In situ mRNA hybridization quantification was performed in the same manner on corresponding sections. Normal urothelium served as the internal control for mRNA expression, and poly-dT staining controlled for mRNA preservation. Results were expressed as the ratio of the intensity of tumor ISH staining to normal urothelium staining and normalized for poly-dT expression.
Statistical Analysis.
Bladder tumor weights were compared by the Mann-Whitney test. Expression of VEGF, IL-8, and bFGF and microvessel density quantification were compared by Student’s t test.
|
Results |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
. Treatment with MAb C225 in 10% serum-containing medium resulted in minimum cytostasis (<20%).
|
. Northern blot analysis directly correlated with the ELISA results (Fig. 3)
. A decrease in the steady-state gene expression of VEGF, IL-8, and bFGF was observed. After treatment, VEGF steady-state mRNA expression was reduced 2-fold, IL-8 expression was reduced 10-fold, and bFGF expression was reduced 2-fold when cells were treated with the high dose of MAb C225 at 10 µg/ml.
|
|
. Treatment of 253J B-V cells with MAb C225 after pretreatment with EGF resulted in inhibition of the production of VEGF, IL-8, and bFGF (Fig. 2B)
. These data support that EGFR blockade by MAb C225 in TCC cells results in decreased expression and protein production of VEGF, IL-8, and bFGF.
Inhibition of Growth and Metastasis of Established Human TCC Tumors in the Bladders of Mice.
Therapy of established 253J B-V tumors commenced 28 days after tumor cells implantation into the bladder wall of athymic nude mice. Therapy of mice with 1 mg of MAb C225 i.p. twice a week for 5 weeks resulted in dramatic tumor regression compared with control with significant reductions in tumor weight and inhibition of metastasis (Table 1)
.4
All control mice harbored lymph node metastases, and approximately 40% demonstrated lung metastases at the time of death. In contrast, none of the MAb C225-treated mice harbored lymph node or lung metastasis at necropsy (P < 0.005). Median tumor weight was reduced from 834 mg in control animals to 67 mg after therapy with MAb C225. This difference in tumor weight represents tumor regression and inhibition of tumor growth because the treated tumors were smaller after completion of therapy than when therapy was initiated. In contrast, in the control group, all mice showed signs of progressive disease and became moribund and were sacrificed within 2–4 weeks of initiating therapy.
|
. After completion of therapy of tumors, the intensity of the expression of VEGF, IL-8, and bFGF message as evaluated by in situ mRNA hybridization in the treated tumors was lower than in control tumors (Fig. 4)
. Computer image analysis of representative sections confirmed a significant reduction in the steady-state mRNA expression for bFGF and IL-8 by week 1 and VEGF by week 3 after initiation of therapy (Fig. 4
, Table 2
). Using immunohistochemical staining, we observed that the immunoreactivity of VEGF, IL-8, and bFGF protein in 253J B-V tumors growing in the bladders of athymic nude mice followed the same pattern of down-regulation after therapy with MAb 225 (Fig. 5
, Table 3
).
|
|
|
|
, 3
). This temporal sequence suggests that the inhibition in the expression of VEGF, IL-8, and bFGF is responsible for the reduction in neovascularity observed in the treated tumors. No significant difference in microvessel density or VEGF, IL-8, and bFGF expression was observed over time within the control tumors. |
Discussion |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
Previously, we reported that the EGFR tyrosine kinase inhibitor CGP 54211 inhibited the growth of 253J B-V tumors established in the bladders of athymic nude mice (20)
. Although the mechanism of this drug was presumed to be cytostatic, we observed fibrosis in the treated tumor consistent with some degree of cytotoxicity. Similarly, our results suggest that the in vivo effect of C225 is a result of cytotoxic activity as well as antiproliferative activity because in vitro maximum cytostasis was only 55% and in vivo there was actual regression of the tumors. The regression of life-threatening hemangiomas of infancy after antiangiogenic therapy with IFN- is a clinical example of the cytotoxic effect of angiogenesis-directed therapy (35)
.
The mechanisms by which EGFR signaling pathways regulate VEGF, IL-8, and bFGF are unclear, but it is established that up-regulation of these factors follows activation of the EGFR signaling pathways by EGF or TGF-. Transcription of VEGF is potentiated by activation of the four AP-1 binding sites within its promoter; the bFGF and IL-8 promoter have one AP-1 site each (36, 37, 38, 39)
. After activation of EGFR signaling pathways, ras and raf are activated, resulting in phosphorylation of c-fos and c-jun, leading to increased AP-1 activity (36
, 40, 41, 42, 43)
. This increase in AP-1 activity leads to transcription of genes with AP-1 sites in their promoter (41
, 42
, 44)
. Because VEGF, IL-8, and bFGF all share AP-1 binding sites, they are potential targets for therapies that down-regulate EGFR signaling pathways, which results in reduced AP-1 activity. Present studies analyzing the promoters of these genes will directly clarify this issue.5
The results of our study support the involvement of EGFR signaling pathways in the regulation of angiogenesis. Induction of EGFR signaling pathways with EGF resulted in overexpression of VEGF, IL-8, and bFGF. Furthermore, EGFR blockade with C225 down-regulated the expression of these factors after EGF induction. Both TGF- and EGF are recognized as potent angiogenic factors. It has been established that EGFR regulates the in vitro expression of VEGF, bFGF, and specified metalloproteinases. Grugel et al. (36)
showed that ras and raf, downstream effectors in the EGFR pathway, stimulate the expression of VEGF and metalloproteinase by NIH 3T3 cells. EGFR activation has also been shown to stimulate VEGF expression by human glioblastoma cells (45)
and to regulate tumor invasion by DU-145 prostate cancer cells (46)
. Petit et al. (17)
reported that in vitro treatment of the human epidermoid carcinoma cell line A431 with MAb C225 down-regulated VEGF and that after in vivo therapy tumors showed reduction in microvessel density counts. Similar observations were reported by Ciardello et al. (47)
using a human colon cancer model.
Collectively, our studies confirm that systemic administration of the chimeric anti-EGFR MAb C225 inhibits growth and metastasis of human TCCs established in the bladder wall of athymic nude mice. We have shown that therapy with MAb C225 has a significant antitumor effect mediated, in part, by inhibition of angiogenesis. The down-regulation of these angiogenic factors produced by the tumor restores the balance between stimulating and inhibitory factors that keeps angiogenesis dormant under normal conditions. The observation that down-regulation of the angiogenic stimulus of the tumor cells inhibits the host angiogenic response emphasizes the complexity of tumor-host interactions. These experiments demonstrate that inhibition of angiogenesis characterizes in part the antitumor effect of therapy directed at inhibiting EGFR signaling pathways in human TCC cells. Furthermore, these experiments indicate that normalization of angiogenesis-related biomarkers such as VEGF, IL-8, bFGF, or microvessel density are clinically useful to demonstrate regression or eradication of cancer after EGFR-directed therapy. Analysis of these biomarkers should be included in clinical trials for evaluating this form of therapy. Finally, combination of this approach with standard chemotherapy may provide increased benefit in patients with advanced TCC.
|
FOOTNOTES |
|---|
1 Supported in part by Cancer Center Core Grant CA 16672, NIH Grants CA 67952 (P.P.) and CA 67914 (C.P.N.D.), and the Gustavus and Louise Pfeiffer Research Foundation. 
2 To whom requests for reprints should be addressed, at The University of Texas M. D. Anderson Cancer Center, Department of Urology-Box 110, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-3250; Fax: (713) 794-4824; E-mail: cdinney{at}notes.mdacc.tmc.edu
3 The abbreviations used are: TCC, transitional cell carcinoma; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; IL-8, interleukin-8; ISH, in situ hybridization; MAb, monoclonal antibody; EGF, epidermal growth factor; EGFR, EGF receptor; EMEM, Eagle’s MEM; FBS, fetal bovine serum; TGF, transforming growth factor.
4 T. Matsumoto, P. Perrotte, D. J. Hicklin, C. P. M. Dinney, and R. Radinsky. Inhibition of human transitional cell carcinoma growing in the bladder of nude mice by anti-EGFR andibody C225: a biomarker analysis. Submitted for publication.
5 P. Perrotte et al., manuscript in preparation.
Received 8/ 6/98; accepted 11/ 9/98.
|
REFERENCES |
|---|
|
TopABSTRACTIntroductionMaterials and MethodsResultsDiscussionREFERENCES |
|---|
-2a therapy for life threatening hemangiomas of infancy. N. Engl. J. Med., 326: 1456-1463, 1992.[Abstract]
This article has been cited by other articles:
|
|
 |
|
  G. K. Philips, S. Halabi, B. L. Sanford, D. Bajorin, E. J. Small, and for the Cancer and Leukemia Group B A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102 Ann. Onc., June 1, 2009; 20(6): 1074 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Levy, G. Sycz, J. M. Arriaga, M. M. Barrio, E. M. von Euw, S. B. Morales, M. Gonzalez, J. Mordoh, and M. Bianchini Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells Innate Immunity, April 1, 2009; 15(2): 91 - 100. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Sano, S. Choi, Z. L. Milas, G. Zhou, C. E. Galer, Y.-W. Su, M. Gule, M. Zhao, Z. Zhu, and J. N. Myers The Effect of Combination Anti-Endothelial Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Receptor 2 Targeted Therapy on Lymph Node Metastasis: A Study in an Orthotopic Nude Mouse Model of Squamous Cell Carcinoma of the Oral Tongue Arch Otolaryngol Head Neck Surg, April 1, 2009; 135(4): 411 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Dickler, H. S. Rugo, C. A. Eberle, E. Brogi, J. F. Caravelli, K. S. Panageas, J. Boyd, B. Yeh, D. E. Lake, C. T. Dang, et al. A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7878 - 7883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Martens, Y. Laabs, H. S. Gunther, D. Kemming, Z. Zhu, L. Witte, C. Hagel, M. Westphal, and K. Lamszus Inhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2 Clin. Cancer Res., September 1, 2008; 14(17): 5447 - 5458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Choi, D. Sano, M. Cheung, M. Zhao, S. A. Jasser, A. J. Ryan, L. Mao, W.-T. Chen, A. K. El-Naggar, and J. N. Myers Vandetanib Inhibits Growth of Adenoid Cystic Carcinoma in an Orthotopic Nude Mouse Model Clin. Cancer Res., August 15, 2008; 14(16): 5081 - 5089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bianco, R. Rosa, V. Damiano, G. Daniele, T. Gelardi, S. Garofalo, V. Tarallo, S. De Falco, D. Melisi, R. Benelli, et al. Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells Clin. Cancer Res., August 15, 2008; 14(16): 5069 - 5080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Hodkinson, A. MacKinnon, and T. Sethi Targeting Growth Factors in Lung Cancer Chest, May 1, 2008; 133(5): 1209 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Prewett, D. S. Deevi, R. Bassi, F. Fan, L. M. Ellis, D. J. Hicklin, and J. R. Tonra Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab Clin. Cancer Res., December 15, 2007; 13(24): 7432 - 7440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tabernero, E. Van Cutsem, E. Diaz-Rubio, A. Cervantes, Y. Humblet, T. Andre, J.-L. Van Laethem, P. Soulie, E. Casado, C. Verslype, et al. Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5225 - 5232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Baselga and J. Tabernero Combined Antiangiogenesis and Antiepidermal Growth Factor Receptor Targeting in the Treatment of Cancer: Hold Back, We Are Not There Yet J. Clin. Oncol., October 10, 2007; 25(29): 4516 - 4518. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Harari, G. W. Allen, and J. A. Bonner Biology of Interactions: Antiepidermal Growth Factor Receptor Agents J. Clin. Oncol., September 10, 2007; 25(26): 4057 - 4065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Damiano, R. Caputo, S. Garofalo, R. Bianco, R. Rosa, G. Merola, T. Gelardi, L. Racioppi, G. Fontanini, S. De Placido, et al. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts PNAS, July 24, 2007; 104(30): 12468 - 12473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tabernero The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wu, W. Yang, R. F. Barth, S. Kawabata, M. Swindall, A. K. Bandyopadhyaya, W. Tjarks, B. Khorsandi, T. E. Blue, A. K. Ferketich, et al. Molecular Targeting and Treatment of an Epidermal Growth Factor Receptor-Positive Glioma Using Boronated Cetuximab Clin. Cancer Res., February 15, 2007; 13(4): 1260 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shrader, M. S. Pino, G. Brown, P. Black, L. Adam, M. Bar-Eli, C. P.N. Dinney, and D. J. McConkey Molecular correlates of gefitinib responsiveness in human bladder cancer cells Mol. Cancer Ther., January 1, 2007; 6(1): 277 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Mitra, R. H. Datar, and R. J. Cote Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification J. Clin. Oncol., December 10, 2006; 24(35): 5552 - 5564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Lenz, E. Van Cutsem, S. Khambata-Ford, R. J. Mayer, P. Gold, P. Stella, B. Mirtsching, A. L. Cohn, A. W. Pippas, N. Azarnia, et al. Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines J. Clin. Oncol., October 20, 2006; 24(30): 4914 - 4921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Jin, K. K. Iwata, A. Belldegrun, R. Figlin, A. Pantuck, Z.-F. Zhang, R. Lieberman, and J. Rao Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol. Cancer Ther., July 1, 2006; 5(7): 1754 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Vincenzi, D. Santini, A. Russo, M. Silletta, M. Gavasci, F. Battistoni, G. Di Cuonzo, L. Rocci, N. Gebbia, and G. Tonini Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients Ann. Onc., May 1, 2006; 17(5): 835 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G. D. Kao, and A. Maity EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1-Independent and HIF-1-Dependent Mechanisms. Cancer Res., March 15, 2006; 66(6): 3197 - 3204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Folprecht, M. P. Lutz, P. Schoffski, T. Seufferlein, A. Nolting, P. Pollert, and C.-H. Kohne Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma Ann. Onc., March 1, 2006; 17(3): 450 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Li, Y-Z Yuan, J Lu, L Xia, Y Zhu, Y-P Zhang, and M-M Qiao Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice Gut, February 1, 2006; 55(2): 259 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kim, C. N. Prichard, M. N. Younes, Y. D. Yazici, S. A. Jasser, B. N. Bekele, and J. N. Myers Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice Clin. Cancer Res., January 15, 2006; 12(2): 600 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Segaert and E. Van Cutsem Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann. Onc., September 1, 2005; 16(9): 1425 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sini, L. Wyder, C. Schnell, T. O'Reilly, A. Littlewood, R. Brandt, N. E. Hynes, and J. Wood The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade Clin. Cancer Res., June 15, 2005; 11(12): 4521 - 4532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Christensen, P. W. Vincent, W. D. Klohs, D. W. Fry, W. R. Leopold, and W. L. Elliott Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor Mol. Cancer Ther., June 1, 2005; 4(6): 938 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Vallbohmer, W. Zhang, M. Gordon, D. Y. Yang, J. Yun, O. A. Press, K. E. Rhodes, A. E. Sherrod, S. Iqbal, K. D. Danenberg, et al. Molecular Determinants of Cetuximab Efficacy J. Clin. Oncol., May 20, 2005; 23(15): 3536 - 3544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. El-Abaseri, J. Fuhrman, C. Trempus, I. Shendrik, R. W. Tennant, and L. A. Hansen Chemoprevention of UV Light-Induced Skin Tumorigenesis by Inhibition of the Epidermal Growth Factor Receptor Cancer Res., May 1, 2005; 65(9): 3958 - 3965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chinnaiyan, S. Huang, G. Vallabhaneni, E. Armstrong, S. Varambally, S. A. Tomlins, A. M. Chinnaiyan, and P. M. Harari Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva) Cancer Res., April 15, 2005; 65(8): 3328 - 3335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kim, B. A. Schiff, O. G. Yigitbasi, D. Doan, S. A. Jasser, B. N. Bekele, M. Mandal, and J. N. Myers Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788 Mol. Cancer Ther., April 1, 2005; 4(4): 632 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tuccillo, M. Romano, T. Troiani, E. Martinelli, F. Morgillo, F. De Vita, R. Bianco, G. Fontanini, R. A. Bianco, G. Tortora, et al. Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor Clin. Cancer Res., February 1, 2005; 11(3): 1268 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science, January 7, 2005; 307(5706): 58 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Camp, J. Summy, T. W. Bauer, W. Liu, G. E. Gallick, and L. M. Ellis Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor Clin. Cancer Res., January 1, 2005; 11(1): 397 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P M Harari Epidermal growth factor receptor inhibition strategies in oncology Endocr. Relat. Cancer, December 1, 2004; 11(4): 689 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Skvortsov, B. Sarg, J. Loeffler-Ragg, I. Skvortsova, H. Lindner, H. Werner Ott, P. Lukas, K. Illmensee, and H. Zwierzina Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment Mol. Cancer Ther., December 1, 2004; 3(12): 1551 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Potti and D. J. George Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6371S - 6376S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Dominguez-Escrig, J. D. Kelly, D. E. Neal, S. M. King, and B. R. Davies Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer Clin. Cancer Res., July 15, 2004; 10(14): 4874 - 4884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Govindan Cetuximab in Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., June 15, 2004; 10(12): 4241S - 4244S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Spiridon, S. Guinn, and E. S. Vitetta A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab')2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies Clin. Cancer Res., May 15, 2004; 10(10): 3542 - 3551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ciardiello, R. Bianco, R. Caputo, R. Caputo, V. Damiano, T. Troiani, D. Melisi, F. De Vita, S. De Placido, A. R. Bianco, et al. Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy Clin. Cancer Res., January 15, 2004; 10(2): 784 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ke, X. Wen, Q.-P. Wu, S. Wallace, C. Charnsangavej, A. M. Stachowiak, C. L. Stephens, J. L. Abbruzzese, D. A. Podoloff, and C. Li Imaging Taxane-Induced Tumor Apoptosis Using PEGylated, 111In-Labeled Annexin V J. Nucl. Med., January 1, 2004; 45(1): 108 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Sosman Targeting of the VHL-Hypoxia-Inducible Factor-Hypoxia-Induced Gene Pathway for Renal Cell Carcinoma Therapy J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2695 - 2702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Uemura, H. Ishiguro, N. Nakaigawa, Y. Nagashima, Y. Miyoshi, K. Fujinami, A. Sakaguchi, and Y. Kubota Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor Mol. Cancer Ther., November 1, 2003; 2(11): 1139 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mendelsohn and J. Baselga Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer J. Clin. Oncol., July 15, 2003; 21(14): 2787 - 2799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Grunwald and M. Hidalgo Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment J Natl Cancer Inst, June 18, 2003; 95(12): 851 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Janmaat, F. A. E. Kruyt, J. A. Rodriguez, and G. Giaccone Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells: Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways Clin. Cancer Res., June 1, 2003; 9(6): 2316 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Abe, K. Terada, H. Wakimoto, R. Inoue, E. Tyminski, R. Bookstein, J. P. Basilion, and E. A. Chiocca PTEN Decreases in Vivo Vascularization of Experimental Gliomas in Spite of Proangiogenic Stimuli Cancer Res., May 1, 2003; 63(9): 2300 - 2305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ciardiello, R. Caputo, V. Damiano, R. Caputo, T. Troiani, D. Vitagliano, F. Carlomagno, B. M. Veneziani, G. Fontanini, A. R. Bianco, et al. Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase Clin. Cancer Res., April 1, 2003; 9(4): 1546 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Kim, H. Uehara, T. Karashima, D. L. Shepherd, J. J. Killion, and I. J. Fidler Blockade of Epidermal Growth Factor Receptor Signaling in Tumor Cells and Tumor-associated Endothelial Cells for Therapy of Androgen-independent Human Prostate Cancer Growing in the Bone of Nude Mice Clin. Cancer Res., March 1, 2003; 9(3): 1200 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Inoue, M. Chikazawa, S. Fukata, C. Yoshikawa, and T. Shuin Docetaxel Enhances the Therapeutic Effect of the Angiogenesis Inhibitor TNP-470 (AGM-1470) in Metastatic Human Transitional Cell Carcinoma Clin. Cancer Res., February 1, 2003; 9(2): 886 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M.L. Ebos, J. Tran, Z. Master, D. Dumont, J. V. Melo, E. Buchdunger, and R. S. Kerbel Imatinib Mesylate (STI-571) Reduces Bcr-Abl-Mediated Vascular Endothelial Growth Factor Secretion in Chronic Myelogenous Leukemia Mol. Cancer Res., December 1, 2002; 1(2): 89 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kedar, C. H. Baker, J. J. Killion, C. P. N. Dinney, and I. J. Fidler Blockade of the Epidermal Growth Factor Receptor Signaling Inhibits Angiogenesis Leading to Regression of Human Renal Cell Carcinoma Growing Orthotopically in Nude Mice Clin. Cancer Res., November 1, 2002; 8(11): 3592 - 3600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mendelsohn Targeting the Epidermal Growth Factor Receptor for Cancer Therapy J. Clin. Oncol., September 15, 2002; 20(90001): 1s - 13. [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Baker, D. Kedar, M. F. McCarty, R. Tsan, K. L. Weber, C. D. Bucana, and I. J. Fidler Blockade of Epidermal Growth Factor Receptor Signaling on Tumor Cells and Tumor-Associated Endothelial Cells for Therapy of Human Carcinomas Am. J. Pathol., September 1, 2002; 161(3): 929 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Baselga Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy Oncologist, August 15, 2002; 7(90004): 2 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Huang, J. Li, E. A. Armstrong, and P. M. Harari Modulation of Radiation Response and Tumor-induced Angiogenesis after Epidermal Growth Factor Receptor Inhibition by ZD1839 (Iressa) Cancer Res., August 1, 2002; 62(15): 4300 - 4306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sweeney, T. Karashima, S.-J. Kim, D. Kedar, B. Mian, S. Huang, C. Baker, Z. Fan, D. J. Hicklin, C. A. Pettaway, et al. Anti-Vascular Endothelial Growth Factor Receptor 2 Antibody Reduces Tumorigenicity and Metastasis in Orthotopic Prostate Cancer Xenografts via Induction of Endothelial Cell Apoptosis and Reduction of Endothelial Cell Matrix Metalloproteinase Type 9 Production Clin. Cancer Res., August 1, 2002; 8(8): 2714 - 2724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Inoue, M. Chikazawa, S. Fukata, C. Yoshikawa, and T. Shuin Frequent Administration of Angiogenesis Inhibitor TNP-470 (AGM-1470) at an Optimal Biological Dose Inhibits Tumor Growth and Metastasis of Metastatic Human Transitional Cell Carcinoma in the Urinary Bladder Clin. Cancer Res., July 1, 2002; 8(7): 2389 - 2398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tedjarati, C. H. Baker, S. Apte, S. Huang, J. K. Wolf, J. J. Killion, and I. J. Fidler Synergistic Therapy of Human Ovarian Carcinoma Implanted Orthotopically in Nude Mice by Optimal Biological Dose of Pegylated Interferon {alpha} Combined with Paclitaxel Clin. Cancer Res., July 1, 2002; 8(7): 2413 - 2422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Spiridon, M.-A. Ghetie, J. Uhr, R. Marches, J.-L. Li, G.-L. Shen, and E. S. Vitetta Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity of a Human Breast Cancer Cell Line in Vitro and in Vivo Clin. Cancer Res., June 1, 2002; 8(6): 1720 - 1730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hirata, S.-i. Ogawa, T. Kometani, T. Kuwano, S. Naito, M. Kuwano, and M. Ono ZD1839 (Iressa) Induces Antiangiogenic Effects through Inhibition of Epidermal Growth Factor Receptor Tyrosine Kinase Cancer Res., May 1, 2002; 62(9): 2554 - 2560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Prewett, A. T. Hooper, R. Bassi, L. M. Ellis, H. W. Waksal, and D. J. Hicklin Enhanced Antitumor Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Combination with Irinotecan (CPT-11) against Human Colorectal Tumor Xenografts Clin. Cancer Res., May 1, 2002; 8(5): 994 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Huang, J. Li, and P. M. Harari Molecular Inhibition of Angiogenesis and Metastatic Potential in Human Squamous Cell Carcinomas after Epidermal Growth Factor Receptor Blockade Mol. Cancer Ther., May 1, 2002; 1(7): 507 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Karashima, P. Sweeney, J. W. Slaton, S. J. Kim, D. Kedar, J. I. Izawa, Z. Fan, C. Pettaway, D. J. Hicklin, T. Shuin, et al. Inhibition of Angiogenesis by the Antiepidermal Growth Factor Receptor Antibody ImClone C225 in Androgen-independent Prostate Cancer Growing Orthotopically in Nude Mice Clin. Cancer Res., May 1, 2002; 8(5): 1253 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Baker, C. C. Solorzano, and I. J. Fidler Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer Cancer Res., April 1, 2002; 62(7): 1996 - 2003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Finley New Directions in the Treatment of Cancer: Inhibition of Signal Transduction Journal of Pharmacy Practice, February 1, 2002; 15(1): 5 - 16. [Abstract] [PDF]
|
|
|
|
|
|
G. Tortora, R. Caputo, V. Damiano, G. Fontanini, D. Melisi, B. Maria Veneziani, F. Zunino, A. R. Bianco, and F. Ciardiello Oral Administration of a Novel Taxane, an Antisense Oligonucleotide Targeting Protein Kinase A, and the Epidermal Growth Factor Receptor Inhibitor Iressa Causes Cooperative Antitumor and Antiangiogenic Activity Clin. Cancer Res., December 1, 2001; 7(12): 4156 - 4163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ciardiello and G. Tortora A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor Clin. Cancer Res., October 1, 2001; 7(10): 2958 - 2970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Slaton, T. Karashima, P. Perrotte, K. Inoue, S. J. Kim, J. Izawa, D. Kedar, D. J. McConkey, R. Millikan, P. Sweeney, et al. Treatment with Low-Dose Interferon-{alpha} Restores the Balance between Matrix Metalloproteinase-9 and E-Cadherin Expression in Human Transitional Cell Carcinoma of the Bladder Clin. Cancer Res., September 1, 2001; 7(9): 2840 - 2853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Solorzano, C. H. Baker, R. Tsan, P. Traxler, P. Cohen, E. Buchdunger, J. J. Killion, and I. J. Fidler Optimization for the Blockade of Epidermal Growth Factor Receptor Signaling for Therapy of Human Pancreatic Carcinoma Clin. Cancer Res., August 1, 2001; 7(8): 2563 - 2572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Viloria-Petit, T. Crombet, S. Jothy, D. Hicklin, P. Bohlen, J. M. Schlaeppi, J. Rak, and R. S. Kerbel Acquired Resistance to the Antitumor Effect of Epidermal Growth Factor Receptor-blocking Antibodies in Vivo: A Role for Altered Tumor Angiogenesis Cancer Res., July 1, 2001; 61(13): 5090 - 5101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Soukos, M. R. Hamblin, S. Keel, R. L. Fabian, T. F. Deutsch, and T. Hasan Epidermal Growth Factor Receptor-targeted Immunophotodiagnosis and Photoimmunotherapy of Oral Precancer in Vivo Cancer Res., June 1, 2001; 61(11): 4490 - 4496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Amara, G. S. Palapattu, M. Schrage, Z. Gu, G. V. Thomas, F. Dorey, J. Said, and R. E. Reiter Prostate Stem Cell Antigen Is Overexpressed in Human Transitional Cell Carcinoma Cancer Res., June 1, 2001; 61(12): 4660 - 4665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Fontanini, S. Cuccato, S. De Placido, A. R. Bianco, and G. Tortora Inhibition of Growth Factor Production and Angiogenesis in Human Cancer Cells by ZD1839 (Iressa), a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Clin. Cancer Res., May 1, 2001; 7(5): 1459 - 1465. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. I. Izawa and C. P.N. Dinney The role of angiogenesis in prostate and other urologic cancers: a review Can. Med. Assoc. J., March 1, 2001; 164(5): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. M. Scholes, S. Hagan, P. Hiscott, B. E. Damato, and I. Grierson Overexpression of Epidermal Growth Factor Receptor Restricted to Macrophages in Uveal Melanoma Arch Ophthalmol, March 1, 2001; 119(3): 373 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gazzaniga, O. Gandini, L. Giuliani, M. Magnanti, A. Gradilone, I. Silvestri, W. Gianni, M. Gallucci, L. Frati, and A. M. Aglianò Detection of Epidermal Growth Factor Receptor mRNA in Peripheral Blood: A New Marker of Circulating Neoplastic Cells in Bladder Cancer Patients Clin. Cancer Res., March 1, 2001; 7(3): 577 - 583. [Abstract] [Full Text]
|
|
|
|
|
|
P. D. Ryan and B. A. Chabner On Receptor Inhibitors and Chemotherapy Clin. Cancer Res., December 1, 2000; 6(12): 4607 - 4609. [Full Text]
|
|
|
|
|
|
K. Inoue, J. W. Slaton, T. Karashima, C. Yoshikawa, T. Shuin, P. Sweeney, R. Millikan, and C. P. N. Dinney The Prognostic Value of Angiogenesis Factor Expression for Predicting Recurrence and Metastasis of Bladder Cancer after Neoadjuvant Chemotherapy and Radical Cystectomy Clin. Cancer Res., December 1, 2000; 6(12): 4866 - 4873. [Abstract] [Full Text]
|
|
|
|
|
|
K. Inoue, J. W. Slaton, P. Perrotte, D. W. Davis, C. J. Bruns, D. J. Hicklin, D. J. McConkey, P. Sweeney, R. Radinsky, and C. P. N. Dinney Paclitaxel Enhances the Effects of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ImClone C225 in Mice with Metastatic Human Bladder Transitional Cell Carcinoma Clin. Cancer Res., December 1, 2000; 6(12): 4874 - 4884. [Abstract] [Full Text]
|
|
|
|
|
|
H. Kuniyasu, W. Yasui, H. Shinohara, S. Yano, L. M. Ellis, M. R. Wilson, C. D. Bucana, T. Rikita, E. Tahara, and I. J. Fidler Induction of Angiogenesis by Hyperplastic Colonic Mucosa Adjacent to Colon Cancer Am. J. Pathol., November 1, 2000; 157(5): 1523 - 1535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Inoue, P. Perrotte, C. G. Wood, J. W. Slaton, P. Sweeney, and C. P. N. Dinney Gene Therapy of Human Bladder Cancer with Adenovirus-mediated Antisense Basic Fibroblast Growth Factor Clin. Cancer Res., November 1, 2000; 6(11): 4422 - 4431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yano, H. Shinohara, R. S. Herbst, H. Kuniyasu, C. D. Bucana, L. M. Ellis, D. W. Davis, D. J. McConkey, and I. J. Fidler Expression of Vascular Endothelial Growth Factor Is Necessary but not Sufficient for Production and Growth of Brain Metastasis Cancer Res., September 1, 2000; 60(17): 4959 - 4967. [Abstract] [Full Text]
|
|
|
|
|
|
F. Ciardiello, R. Bianco, V. Damiano, G. Fontanini, R. Caputo, G. Pomatico, Sabino De Placido, A. R. Bianco, J. Mendelsohn, and G. Tortora Antiangiogenic and Antitumor Activity of Anti-Epidermal Growth Factor Receptor C225 Monoclonal Antibody in Combination with Vascular Endothelial Growth Factor Antisense Oligonucleotide in Human GEO Colon Cancer Cells Clin. Cancer Res., September 1, 2000; 6(9): 3739 - 3747. [Abstract] [Full Text]
|
|
|
|
|
|
K. Inoue, J. W. Slaton, D. W. Davis, D. J. Hicklin, D. J. McConkey, T. Karashima, R. Radinsky, and C. P. N. Dinney Treatment of Human Metastatic Transitional Cell Carcinoma of the Bladder in a Murine Model with the Anti-Vascular Endothelial Growth Factor Receptor Monoclonal Antibody DC101 and Paclitaxel Clin. Cancer Res., July 1, 2000; 6(7): 2635 - 2643. [Abstract] [Full Text]
|
|
|
|
|
|
C. J. Bruns, C. C. Solorzano, M. T. Harbison, S. Ozawa, R. Tsan, D. Fan, J. Abbruzzese, P. Traxler, E. Buchdunger, R. Radinsky, et al. Blockade of the Epidermal Growth Factor Receptor Signaling by a Novel Tyrosine Kinase Inhibitor Leads to Apoptosis of Endothelial Cells and Therapy of Human Pancreatic Carcinoma Cancer Res., June 1, 2000; 60(11): 2926 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Huang and P. M. Harari Modulation of Radiation Response after Epidermal Growth Factor Receptor Blockade in Squamous Cell Carcinomas: Inhibition of Damage Repair, Cell Cycle Kinetics, and Tumor Angiogenesis Clin. Cancer Res., June 1, 2000; 6(6): 2166 - 2174. [Abstract] [Full Text]
|
|
|
|
|
|
C. J. Bruns, M. T. Harbison, D. W. Davis, C. A. Portera, R. Tsan, D. J. McConkey, D. B. Evans, J. L. Abbruzzese, D. J. Hicklin, and R. Radinsky Epidermal Growth Factor Receptor Blockade with C225 Plus Gemcitabine Results in Regression of Human Pancreatic Carcinoma Growing Orthotopically in Nude Mice by Antiangiogenic Mechanisms Clin. Cancer Res., May 1, 2000; 6(5): 1936 - 1948. [Abstract] [Full Text]
|
|
|
|
|
|
K. Inoue, J. W. Slaton, B. Y. Eve, S. J. Kim, P. Perrotte, M. D. Balbay, S. Yano, M. Bar-Eli, R. Radinsky, C. A. Pettaway, et al. Interleukin 8 Expression Regulates Tumorigenicity and Metastases in Androgen-independent Prostate Cancer Clin. Cancer Res., May 1, 2000; 6(5): 2104 - 2119. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. V. Ngo, M. Gee, N. Akhtar, D. Yu, O. Volpert, R. Auerbach, and A. Thomas-Tikhonenko An in Vivo Function for the Transforming Myc Protein: Elicitation of the Angiogenic Phenotype Cell Growth Differ., April 1, 2000; 11(4): 201 - 210. [Abstract] [Full Text]
|
|
|
|
|
|
K. Inoue, J. W. Slaton, S. J. Kim, P. Perrotte, B. Y. Eve, M. Bar-Eli, R. Radinsky, and C. P. N. Dinney Interleukin 8 Expression Regulates Tumorigenicity and Metastasis in Human Bladder Cancer Cancer Res., April 1, 2000; 60(8): 2290 - 2299. [Abstract] [Full Text]
|
|
|
|
|
|
A. D. Perera, E. V. Kleymenova, and C. L. Walker Requirement for the von Hippel-Lindau Tumor Suppressor Gene for Functional Epidermal Growth Factor Receptor Blockade by Monoclonal Antibody C225 in Renal Cell Carcinoma Clin. Cancer Res., April 1, 2000; 6(4): 1518 - 1523. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. S. Kerbel Tumor angiogenesis: past, present and the near future Carcinogenesis, March 1, 2000; 21(3): 505 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mendelsohn Blockade of Receptors for Growth Factors: An Anticancer Therapy -- The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture Clin. Cancer Res., March 1, 2000; 6(3): 747 - 753. [Full Text]
|
|
|
|
|
|
P. M. Harari and S.-M. Huang Modulation of Molecular Targets to Enhance Radiation Clin. Cancer Res., February 1, 2000; 6(2): 323 - 325. [Full Text]
|
|
|
|
|
|
L. Milas, K. Mason, N. Hunter, S. Petersen, M. Yamakawa, K. Ang, J. Mendelsohn, and Z. Fan In Vivo Enhancement of Tumor Radioresponse by C225 Antiepidermal Growth Factor Receptor Antibody Clin. Cancer Res., February 1, 2000; 6(2): 701 - 708. [Abstract] [Full Text]
|
|
|
|
|
|
J. Rak, Y. Mitsuhashi, C. Sheehan, A. Tamir, A. Viloria-Petit, J. Filmus, S. J. Mansour, N. G. Ahn, and R. S. Kerbel Oncogenes and Tumor Angiogenesis: Differential Modes of Vascular Endothelial Growth Factor Up-Regulation in ras-transformed Epithelial Cells and Fibroblasts Cancer Res., January 1, 2000; 60(2): 490 - 498. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
